Phage therapy program
PHAGENIX
| Status | Research/development |
|---|---|
| Type | Company |
| Location | Lyon; France |
| Entry review | 2026-10-03 |
Access and enquiries
| How to enquire | Current corporate/health-professional contact form; no general patient intake or expanded-access policy established. |
|---|---|
| Areas of work | Site describes a specialty-pharmaceutical company established in 2025 with S. aureus, E. coli and P. aeruginosa phage portfolios. |
| International access | No current general international patient access policy established. |
What to confirm
- Image-only clinical portfolio did not provide reliable text-based current recruitment detail.
- Legal succession from PHAXIAM and continued compassionate supply need confirmation.
- Registry sponsor-name continuity is not proof of legal asset transfer; PhagoDAIR has ended.
Related studies(2)
PhagoDAIRI
Ended
Recorded program–study link. Website
GLORIA
Not yet recruiting
Recorded program–study link. Website
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
- PHAGENIX mission and history
- PHAGENIX contact
- ClinicalTrials.gov NCT06605651
- CTIS 2024-516555-40-00
- CTIS 2024-516207-17-00
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Program ID | eu-phagenix |
|---|